GlassScriptPhysician profile
Alexander Prattes
NPI 1144318346
$5,644.30
in general payments reported to CMS, 2019-2025
20 companies · $15.05 in 2025
The $15.05 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,427 · 2020: $708 · 2021: $1,044 · 2022: $416 · 2024: $34.24 · 2025: $15.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $893.50 | 2019-2025 | Wainua |
| Amarin Pharma, INC. | $716.51 | 2019-2021 | |
| Lilly USA, LLC | $684.47 | 2019-2021 | |
| Novo Nordisk INC | $631.57 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $389.86 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.87 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.62 | 2019-2021 | |
| Amgen INC. | $269.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $234.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $214.09 | 2019-2021 | |
| Esperion Therapeutics, INC. | $208.13 | 2021-2022 | |
| Abbvie INC. | $202.51 | 2019 | |
| Astellas Pharma US INC | $166.98 | 2019 | |
| Daiichi Sankyo INC. | $105.28 | 2019 | |
| Celgene Corporation | $105.26 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $92.50 | 2019 | |
| Allergan, INC. | $47.79 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.24 | 2024 | Entyvio |
| Glaxosmithkline, LLC. | $23.75 | 2021 | |
| Livanova USA, INC. | $18.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Prattes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.